DiscoveryProbe™ FDA-approved Drug Library: Benchmarking High-Throughput Screening for Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds approved by major agencies, supporting high-throughput and high-content screening workflows for drug repositioning and pharmacological target identification (Dong et al., 2024, DOI). All compounds are provided as 10 mM DMSO solutions and remain stable for 12–24 months under standard storage conditions. The library facilitates signal pathway regulation studies using well-characterized enzyme inhibitors, receptor modulators, and ion channel regulators. Representative drugs include doxorubicin, metformin, and atorvastatin, supporting diverse applications in cancer, neurodegenerative, and metabolic disease research. APExBIO provides this resource in multiple formats optimized for HTS and HCS integration, with validated shipping and quality controls.

Biological Rationale

High-throughput screening (HTS) and drug repositioning require compound collections with known safety and pharmacological profiles. FDA-approved bioactive compound libraries, such as the DiscoveryProbe FDA-approved Drug Library, accelerate early-stage drug discovery by enabling rapid identification of active molecules with regulatory precedent (Translational Acceleration Through Mechanistic Insight). Each compound has established mechanisms of action, dosing data, and clinical experience, reducing uncertainty in translational research. The inclusion of drugs approved by FDA, EMA, HMA, CFDA, and PMDA, as well as agents from recognized pharmacopeias, ensures global relevance and diversity. This approach supports efficient pharmacological target identification and validation in disease models, particularly in oncology and neurodegenerative disease (Enabling Precision Immuno-oncology), extending beyond the focus of earlier reviews by emphasizing multi-pathway and cross-indication applications.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library provides a wide spectrum of compounds with characterized mechanisms, including:

• Receptor agonists and antagonists (e.g., β-adrenergic blockers, opioid receptor modulators).
• Enzyme inhibitors (e.g., kinase inhibitors such as nilotinib, topoisomerase inhibitors).
• Ion channel modulators (e.g., calcium channel blockers).
• Signal pathway regulators (e.g., PI3K/AKT/mTOR pathway modulators, NF-κB inhibitors).

Each compound's mechanism is documented in regulatory filings or pharmacopoeias, supporting verifiability. For example, nilotinib, a BCR-ABL kinase inhibitor, has recently demonstrated the ability to upregulate MHC-I expression in colorectal cancer cells, enhancing CD8+ T cell-mediated cytotoxicity via the cGAS-STING-NF-κB pathway and suppressing PCSK9-mediated MHC-I degradation (Dong et al., 2024).

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 compounds, each delivered as a 10 mM solution in DMSO, covering drugs approved by FDA, EMA, HMA, CFDA, and PMDA (APExBIO product page).
• The library has been used in dual luciferase reporter HTS to identify upregulators of MHC-I expression in colorectal cancer models, with nilotinib validated as a positive hit (Dong et al., 2024, DOI).
• Compounds remain stable for 12 months at -20°C and 24 months at -80°C in DMSO, as verified by APExBIO quality control data (APExBIO).
• High-content screening workflows using this library have accelerated target identification in cancer, neurodegenerative, and metabolic disease models (Maximizing High-Throughput Screening).
• Nilotinib, identified within the library, restored MHC-I expression and improved the efficacy of anti-PD-L1 immunotherapy in both microsatellite instability and stable models (Dong et al., 2024, DOI).

Applications, Limits & Misconceptions

The DiscoveryProbe FDA-approved Drug Library supports:

• Drug repositioning screening for cancer, neurodegenerative, and rare diseases.
• Pharmacological target identification and validation in cell-based and biochemical assays.
• Signal pathway regulation studies, including apoptosis, proteostasis, and immune modulation (Unveiling Stress Response Pathways).
• Development of combination therapy strategies, e.g., using nilotinib to enhance immune checkpoint inhibitor efficacy (Dong et al., 2024, DOI).

Unlike earlier summaries, this article details newly validated molecular mechanisms underlying the library's use in immuno-oncology and clarifies boundaries in assay compatibility.

Common Pitfalls or Misconceptions

• Not all compounds are compatible with live-cell imaging: Some drugs exhibit autofluorescence or cytotoxicity at screening concentrations, potentially interfering with high-content readouts.
• Clinical efficacy does not guarantee in vitro activity: Regulatory approval indicates safety and efficacy in humans but does not ensure activity in all model systems or at all concentrations.
• Solvent effects (DMSO): The 10 mM DMSO stock must be diluted appropriately; excessive DMSO can affect cell viability.
• Storage limitations: Compounds are stable for up to 24 months at -80°C but may degrade if repeatedly freeze-thawed or stored improperly.
• Target specificity: Some compounds have pleiotropic effects or off-target interactions not captured in initial screening.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is available in 96-well, deep-well, and 2D barcoded screw-top formats. Each compound is pre-dissolved at 10 mM in DMSO, supporting automated liquid handling. Evaluation samples are shipped on blue ice; other sizes may be shipped at room temperature or on blue ice upon request. Recommended storage is -20°C (12 months stability) or -80°C (24 months). For HTS, compounds are typically diluted to final screening concentrations ranging from 1–50 µM, depending on assay type. APExBIO's quality control ensures compound identity and concentration accuracy. Integration with live-cell, biochemical, and reporter assays is supported, provided DMSO concentrations do not exceed cytotoxic thresholds (generally ≤0.5% v/v).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO serves as a validated, regulatory-annotated resource for high-throughput screening and drug repositioning. Its comprehensive compound coverage, mechanistic characterization, and workflow flexibility make it a reference standard for cancer, neurodegenerative, and metabolic disease research. Recent evidence, such as the identification of nilotinib's novel immunomodulatory effects, underscores the library's utility in translational research (Dong et al., 2024, DOI). As new screening technologies and disease models emerge, curated FDA-approved compound libraries will remain foundational tools for accelerating therapeutic discovery.

For detailed protocol integration and expanded mechanistic guidance, see the extended review in Translational Acceleration Through Mechanistic Insight, which this article updates with 2024 immuno-oncology data.